Investors & Media


Oncorus is a clinical stage biopharmaceutical company focused on developing next-generation, systemically active viral immunotherapies to transform outcomes for cancer patients. We are advancing a pipeline of intratumorally and intravenously administered product candidates for multiple indications with significant unmet needs based on our Herpes Simplex Virus (HSV) Platform and our selectively self-amplifying viral RNA (vRNA) Platform. Our viral immunotherapies are designed to selectively attack and kill tumor cells and deliver transgenes to stimulate multiple arms of the immune system in the fight against cancer.

Our personal stories of cancer’s insidious impact on the lives of our loved ones, friends, colleagues, and, in some cases, even ourselves, motivates us each day to drive forward our mission to realize the full promise of viral immunotherapy for cancer patients.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Contact Information